Mannatech (MTEX) Competitors

$4.37 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

MTEX vs. ALGS, PPCB, APLM, QUCY, and MYNZ

Should you buy Mannatech stock or one of its competitors? MarketBeat compares Mannatech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mannatech include Aligos Therapeutics (ALGS), Propanc Biopharma (PPCB), Apollomics (APLM), Mainz Biomed (QUCY), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.

How does Mannatech compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Mannatech has a net margin of -11.97% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Mannatech	-11.97%	-2,383.34%	-40.24%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aligos Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Aligos Therapeutics currently has a consensus price target of $37.20, suggesting a potential upside of 545.83%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mannatech has higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	16.28	-$24.19M	-$8.69	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

In the previous week, Mannatech had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Mannatech and 2 mentions for Aligos Therapeutics. Mannatech's average media sentiment score of 0.85 beat Aligos Therapeutics' score of 0.64 indicating that Mannatech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mannatech	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mannatech beats Aligos Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Mannatech compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Propanc Biopharma has a beta of 3.59, suggesting that its stock price is 259% more volatile than the broader market. Comparatively, Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

13.0% of Mannatech shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mannatech has higher revenue and earnings than Propanc Biopharma. Propanc Biopharma is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$0.97	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

In the previous week, Mannatech had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 7 mentions for Mannatech and 4 mentions for Propanc Biopharma. Mannatech's average media sentiment score of 0.85 beat Propanc Biopharma's score of -0.72 indicating that Mannatech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Mannatech	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Propanc Biopharma has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Propanc Biopharma's return on equity of -151.28% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Mannatech	-11.97%	-2,383.34%	-40.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mannatech beats Propanc Biopharma on 8 of the 12 factors compared between the two stocks.

How does Mannatech compare to Apollomics?

Mannatech (NASDAQ:MTEX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Mannatech has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Apollomics' return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Apollomics	N/A	N/A	N/A

Apollomics has lower revenue, but higher earnings than Mannatech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mannatech had 7 more articles in the media than Apollomics. MarketBeat recorded 7 mentions for Mannatech and 0 mentions for Apollomics. Mannatech's average media sentiment score of 0.85 beat Apollomics' score of 0.00 indicating that Mannatech is being referred to more favorably in the media.

Company	Overall Sentiment
Mannatech	Positive
Apollomics	Neutral

Summary

Apollomics beats Mannatech on 7 of the 11 factors compared between the two stocks.

How does Mannatech compare to Mainz Biomed?

Mannatech (NASDAQ:MTEX) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Mannatech has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Mainz Biomed has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Mainz Biomed's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Mainz Biomed	N/A	N/A	N/A

Mannatech has higher revenue and earnings than Mainz Biomed. Mannatech is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A
Mainz Biomed	$540K	90.40	-$16.21M	-$65.60	N/A

In the previous week, Mannatech had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for Mannatech and 6 mentions for Mainz Biomed. Mannatech's average media sentiment score of 0.85 beat Mainz Biomed's score of 0.03 indicating that Mannatech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

13.0% of Mannatech shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 9.8% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Mannatech beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

How does Mannatech compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

Mainz Biomed has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Mainz Biomed's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Mannatech	-11.97%	-2,383.34%	-40.24%

In the previous week, Mannatech had 7 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for Mannatech and 0 mentions for Mainz Biomed. Mannatech's average media sentiment score of 0.85 beat Mainz Biomed's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Mannatech	Positive

13.0% of Mannatech shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Mannatech beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTEX vs. The Competition

Export

Metric	Mannatech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.43M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.65	17.79	21.00	25.66
Price / Sales	0.08	336.21	562.18	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	-1.52	5.86	10.41	7.14
Net Income	-$15.21M	$74.99M	$3.57B	$335.98M
7 Day Performance	3.80%	3.11%	6.40%	4.11%
1 Month Performance	-8.19%	-3.05%	3.54%	2.52%
1 Year Performance	-55.63%	34.38%	34.14%	35.04%

Mannatech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTEX Mannatech	1.3611 of 5 stars	$4.37 flat	N/A	-55.6%	$8.43M	$108.04M	N/A	250
ALGS Aligos Therapeutics	3.1878 of 5 stars	$5.18 -3.4%	$41.50 +701.2%	+4.7%	$32.06M	$2.19M	N/A	90
PPCB Propanc Biopharma	0.4566 of 5 stars	$2.01 -2.0%	N/A	-97.7%	$31.88M	N/A	N/A	1	Gap Down
APLM Apollomics	0.8542 of 5 stars	$14.36 -4.3%	N/A	+100.7%	$31.58M	$8.50M	N/A	45
QUCY Mainz Biomed	0.6529 of 5 stars	$2.52 -23.6%	N/A	N/A	$31.54M	$537.08K	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTEX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mannatech (MTEX) Competitors

MTEX vs. ALGS, PPCB, APLM, QUCY, and MYNZ

How does Mannatech compare to Aligos Therapeutics?

Summary

How does Mannatech compare to Propanc Biopharma?

Summary

How does Mannatech compare to Apollomics?

Summary

How does Mannatech compare to Mainz Biomed?

Summary

How does Mannatech compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mannatech (MTEX) Competitors

MTEX vs. ALGS, PPCB, APLM, QUCY, and MYNZ

How does Mannatech compare to Aligos Therapeutics?

Is ALGS or MTEX more profitable?

Do institutionals and insiders have more ownership in ALGS or MTEX?

Which has more volatility and risk, ALGS or MTEX?

Do analysts recommend ALGS or MTEX?

Which has stronger earnings and valuation, ALGS or MTEX?

Does the media refer more to ALGS or MTEX?

Summary

How does Mannatech compare to Propanc Biopharma?

Which has more volatility and risk, PPCB or MTEX?

Do institutionals and insiders believe in PPCB or MTEX?

Which has preferable valuation & earnings, PPCB or MTEX?

Does the media refer more to PPCB or MTEX?

Is PPCB or MTEX more profitable?

Do analysts rate PPCB or MTEX?

Summary

How does Mannatech compare to Apollomics?

Which has more volatility & risk, MTEX or APLM?

Do analysts rate MTEX or APLM?

Is MTEX or APLM more profitable?

Which has stronger earnings and valuation, MTEX or APLM?

Do institutionals & insiders believe in MTEX or APLM?

Does the media prefer MTEX or APLM?

Summary

How does Mannatech compare to Mainz Biomed?

Which has more risk and volatility, MTEX or QUCY?

Is MTEX or QUCY more profitable?

Which has better valuation and earnings, MTEX or QUCY?

Does the media prefer MTEX or QUCY?

Do analysts rate MTEX or QUCY?

Do insiders & institutionals believe in MTEX or QUCY?

Summary

How does Mannatech compare to Mainz Biomed?

Do analysts recommend MYNZ or MTEX?

Which has more volatility and risk, MYNZ or MTEX?

Which has preferable valuation & earnings, MYNZ or MTEX?

Is MYNZ or MTEX more profitable?

Does the media refer more to MYNZ or MTEX?

Do insiders and institutionals have more ownership in MYNZ or MTEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools